Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan

BACKGROUND: Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia. METHODS: This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat’s noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemi...

Full description

Saved in:
Bibliographic Details
Published in:J Am Soc Nephrol
Main Authors: Akizawa, Tadao, Iwasaki, Manabu, Yamaguchi, Yusuke, Majikawa, Yoshikatsu, Reusch, Michael
Format: Artigo
Language:Inglês
Published: American Society of Nephrology 2020
Subjects:
Clinical Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7350993/
https://ncbi.nlm.nih.gov/pubmed/32493693
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019060623
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items